Merck and a woman suing the drugmaker agreed to halt a trial over alleged injuries from the drugmaker's human papillomavirus ...
Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations with Keytruda sales.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback